Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Cabozantinib and Pembrolizumab for the Treatment of Metastatic Pancreatic Cancer

Trial Status: closed to accrual and intervention

This phase II trial tests whether cabozantinib and pembrolizumab works to shrink tumors in patients with pancreatic cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may help control the disease in patients with metastatic pancreatic cancer.